New England Journal of Medicine· 2013Q1
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- 1,131citations
- Q1SCImago
- 2013year
Short summary
Ponatinib achieved significant antileukemic activity in heavily pretreated patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL), including those with the T315I mutation resistant to other TKIs.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Hematology
HematologyMedicine